- Better hemodynamic stability and lower rates of post-operative shock
- Patients in the CytoSorb group had lower median Vasoactive-Inotropic Scores (27.2 [14.6–47.7] vs. 41.9 [22.4–63.2], p=0.046) and Vasoplegic Syndrome rates (20.0% vs 48.0% control, p=0.028)
- The odds of early Vasoplegic Syndrome were 6.4 times lower in the CytoSorb group (p=0.029).
- Shorter median time on mechanical ventilation
- 25 [19–68.8] hours vs. 65 [23–287] hours in control, p=0.025
- Lower rates of acute kidney injury (AKI) and need for renal replacement therapy (RRT)
- AKI: 36.7% vs. 76.0% control, p=0.004
- Renal replacement therapy: 0% vs. 16.0% control, p=0.037
- Shorter median time in the ICU
- 8.5 [8.0–10.3] days vs. 12 [8.5–18.0] days in control, p=0.022
- No relevant removal of the anti-rejection drug mycophenolic acid (MPA)
- Similar rates of cardiac allograft rejection, 30-day mortality, and 1-year survival between groups
- There were no reported device-related adverse events during the study period
CytoSorbents Reports Outcomes From A Randomized Controlled Trial Using CytoSorb Blood Purification During Heart Transplant, Recently Published In The European Society Of Cardiology Journal, ESC Heart Failure
Better hemodynamic stability and lower rates of post-operative shock
Patients in the CytoSorb group had lower median Vasoactive-Inotropic Scores (27.2 [14.6–47.7] vs. 41.9 [22.4–63.2], p=0.046) and
Related Posts
BYD Plans European Expansion With New Manufacturing Plant In Hungary: Report
Chinese electric vehicle company BYD Co., Ltd. (OTC: BYDDY) (OTC: BYDDF) reportedly plans to bui
5 Value Stocks In The Energy Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices…
Here’s How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 1.48% on an annualized basis…